Level Brands Inc. (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses, and BMG, a multinational record label and the world’s fourth-largest music-publishing company, announced Tues., May 8, 2018 the signing of a three-project music deal with Level Brands’ Encore Endeavor One (EE1), which develops music, film, radio, and television content and affordable, interactive experiences for families. The new label-distributor association was announced jointly by Stephen Roseberry, President of EE1, and Hartwig Masuch, Chief Executive Officer of BMG.
The Background: The new association will begin with a project involving classic songs selected from the John Lennon-Paul McCartney catalogue and will include music videos. The first project is “Blackbird,” a song Sir Paul McCartney acknowledges was inspired by the civil-rights revolution in America in the 1960s. The project artists will be selected from among Grammy Award winners as well as new emerging artists.
Key Quote: Kathy Ireland®, Chairman Emeritus and Chief Brand Strategist for Level Brands, said: “Our new project with BMG is a strategic and important step in our goal to help Level Brands become a global conglomerate and a dominant force in the branding and marketing space across multiple categories.”
Why It Matters: Roseberry said the three-project deal will identify artists “who can bring a contemporary interpretation to classic pop tunes, as well as reconnect legendary artists with their audiences. ... We are targeting a large market opportunity, as according to the IFPI Global Music Report, in 2016, pop music accounted for 15.7% of music consumption and rock music 24.5%.”
Disclosure
(Level Brands [NYSE: LEVB] is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services.)
262 words
Nutriband (OTC: NTRB) Joins RedChip Nation
Nutriband (OTC: NTRB) is the latest company to join the RedChip Nation. The unique, results-driven health and pharmaceutical company is developing and commercializing a portfolio of OTC products and pharmaceuticals based on the science of transdermal/topical technologies.
Why It Matters: Transdermal prescription sales are projected to reach $125 billion by 2021 (11.6% CAGR), while health-supplement sales could surpass $278 billion by 2024 (8.8% CAGR). Through a series of acquisitions, Nutriband is ideally positioned to capitalize on these trends and expects to grow revenue to $198 million by 2020.
What’s Next: The Company’s IP portfolio was independently valued at $120.7 million before its April 2018 acquisition of 4P Therapeutics, a revenue-generating, third-party clinical-development specialist with a robust IP portfolio. The 4P acquisition adds Defent™ abuse-deterrent patch technology, an opioid abuse-deterrent platform for the transdermal delivery of opioid-based medications. The acquisition also adds Exenatide, a Phase 1-2 injection-free alternative for patients with Type 2 diabetes, as well as a pipeline of other innovative development programs.
Nutriband currently sells three OTC products (energy, weight management, and vitamin patches). Revenue for FY18 is forecasted to reach $4.2 million, growing to $198 million by 2020. Key growth drivers include expanding OTC product lines and ongoing development of the Company’s robust portfolio of pharmaceutical and diagnostic transdermal technologies. Achieving a fraction of its growth targets would provide significant improvement in shareholder value, which should be reflected in a much higher market cap long-term.
Disclosure
(Nutriband Inc. [OTC:NTRB] is a client of RedChip Companies, Inc. NTRB agreed to pay RedChip Companies, Inc. 10,000 shares of Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.)
Immuron Limited (NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, announced on Mon., May 7 the successful completion of its colitis preclinical program at the University of Zurich, Switzerland.
The Background: Immuron reported that oral administration of IMM-124E was able to treat mice with immunologically induced colitis. The University of Zurich research revealed that IMM-124E offered a significant therapeutic benefit on clinically meaningful study parameters. In contrast to the results reported in April 2017 using an acute colitis model, these latest results were generated in the T cell transfer model, which utilizes immunodeficient mice (deficient in functional B and T lymphocytes). In this model, chronic colitis is induced immunologically, not chemically. IMM-124E was administered orally after the onset of colitis symptoms such as weight loss and macroscopically inflamed colon were confirmed by colonoscopy before initiation of treatment.
Why It Matters: The results clearly demonstrated that oral treatment with IMM-124E resulted in significant alleviation of colitis symptoms, among them reduced weight loss, reduced disease-activity scores, reduced shortening of the colon, and reduced levels of macroscopically detectable colitis.
Key Quote: “The IMM-124E drug candidate has been developed to target the endotoxin LPS in the gut and prevent it translocating into the portal circulation. This first-in-class mechanism of action was recently confirmed in our non-alcoholic steatohepatitis (NASH) clinical study, where IMM-124E demonstrated a statistically significant reduction in serum LPS levels when compared to placebo in patients with biopsy-confirmed NASH. The University of Zurich research program adds to our published preclinical and clinical data, which has repeatedly shown that IMM-124E delivers a significant reduction in liver and mucosal inflammation. LPS endotoxins have been widely implicated as a major driver of inflammation in colitis, inflammatory bowel disease (IBD), NASH, as well as numerous auto-immune diseases.” — Jerry Kanellos, Immuron Interim CEO
Disclosure
(Immuron Ltd. [NASDAQ: IMRN] is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services, which includes this research report. )
Addus HomeCare Corporation (NASDAQ: ADUS), a provider of comprehensive home care services, reported strong first quarter results on Monday, with net services revenue up 7.7% to $109 million and net income up 14.1% to $4.9 million.
Why It Matters: The Q1 results are the first to show the impact from recent tax-reform measures. With net income up nearly double its revenue growth rate, the results look extremely positive.
Key Quote: “Our first-quarter financial results and acquisition pipeline position Addus for continued growth during 2018.” – Dirk Allison, President & CEO
What’s Next: Addus has closed two acquisitions since the close of Q1: Ambercare and Arcadia Home Care & Staffing. Both are expected to be immediately accretive to earnings. Combined, these two companies generated more than $100 million in sales in 2017. With more acquisitions in the pipeline, the company is positioned for great growth in 2018.
Global Brass and Copper Holdings (NASDAQ: BRSS), a leading value-added converter, fabricator, processor, and distributor of specialized metal products, reported impressive Q1 results last week, with net sales up 12.4% to $472 million. Net income was down slightly year-over-year to $0.71 per diluted share.
Key Quote: “Our cash position continues to be strong, and we remain focused on driving profitable growth.” – John Wasz, President & CEO
What’s Next: Global Brass reaffirmed its full-year 2018 guidance, with adjusted EBITDA expected to range from $127 million to $137 million. It also declared its quarterly dividend of $0.06 per share for stockholders of record on the close of business on May 15, 2018.
If Egyptian billionaire Naguib Sawiri is right, then gold is heading for a big increase from its current level of about $1,315/oz.—to perhaps $1,800/oz., an increase of 37%.
The Background: Sawiri recently told Bloomberg that a combination of multiplying world crises, crashing stock markets (which Sawiri said are “overvalued”), and continuing high consumption by the Chinese will lead to a situation where gold will leap upward in price.
Why It Matters: Such a scenario would be a big deal to mining and exploration enterprises such as Santa Fe Gold Corporation (OTC Pink: SFEG). SFEG concentrates on gold, silver, copper, and precious, industrial, and base metals. SFEG operates a portfolio of properties in New Mexico, Alaska, Canada, and Central America. The goal of the Company is to produce significant cash flow from precious-metals holdings while creating a portfolio of high-quality exploration and bankable development projects that will ensure future revenue growth.
Key Quote: “Santa Fe Gold is currently pursuing several key value-oriented strategic initiatives that can be expected to significantly enhance shareholder value, through the implementation of a number of innovative financial strategies that we anticipate will add substantial income and intrinsic value to Santa Fe Gold’s balance sheet.”— Tom Laws, President, Director, and Chief Executive Officer, Santa Fe Gold Corp.
Disclosure
(Santa Fe Gold Corp. [OTC:SFEG] is a client of RedChip Companies, Inc. SFEG agreed to pay RedChip Companies, Inc. 1,000,000 shares of Rule 144 stock for 12 months of RedChip investor awareness services and consulting services.)
Seeking Alpha contributor James Picerno recently looked at the year-to-date performance of popular exchange-traded funds.
Notably, the small-cap focused iShares Russell 2000 ETF (NYSE: IWM) outperformed, up 3.3% as of the report, while the large-cap focused Russell 1000 ETF (NYSE: IWB) was up just 1.7% during the period.
Quote of the Week
"Higher returns, of course, come with more risk...the trade off is, yes, you get long-term
outperformance ... but the volatility of returns is greater... That's the price you pay if you
want exposure to a better-performing asset class."
- Harold Stonechipher, Founder of Pre-Paid Legal
IDXG Fact Sheet: Interpace Diagnostics (NASDAQ: IDXG) is a fully integrated commercial organization that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. - March 2018
TPIV Fact Sheet: TapImmune (NASDAQ: TPIV) develops immunotherapies targeting tumors and metastatic diseases for a variety of cancers. The Company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer-vaccine approaches. - March 2018
IMRN Fact Sheet: Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. - March 2018
DGLY Fact Sheet: Digital Ally® (NASDAQ: DGLY) headquartered in Lenexa, Kan., specializes in the design and manufacture of the highest-quality video-recording equipment and video-analytic software. In industries such as law enforcement, emergency management, commercial fleets, and consumer use, Digital Ally pushes the boundaries of technology. - March 2018
CATS Fact Sheet: Catasys Inc. (NASDAQ: CATS) harnesses proprietary big-data predictive analytics, artificial intelligence, and telehealth. These elements, combined with human intervention and integrated, technology-enabled treatment solutions, deliver improved health to members and cost savings to health plans- March 2018
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
